We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

78 hedge funds and large institutions have $28.8M invested in Galectin Therapeutics in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

1.12% more ownership

Funds ownership: 16.58% → 17.69% (+1.1%)

3% less funds holding

Funds holding: 80 → 78 (-2)

16% less capital invested

Capital invested by funds: $34.4M → $28.8M (-$5.66M)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

48% less call options, than puts

Call options by funds: $453K | Put options by funds: $865K

Holders
78
Holders Change
-2
Holders Change %
-2.5%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
25
Reduced
10
Closed
10
Calls
$453K
Puts
$865K
Net Calls
-$412K
Net Calls Change
+$96K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$995K
2
State Street
State Street
Massachusetts
+$400K
3
Morgan Stanley
Morgan Stanley
New York
+$299K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$257K
5
VF
Virtu Financial
New York
+$190K

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$149K
2
WG
Winton Group
United Kingdom
-$111K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$105K
4
Jane Street
Jane Street
New York
-$88K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$60K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$112K +$136K +39,100 New
William Blair & Company
27
William Blair & Company
Illinois
$98K – – –
Goldman Sachs
28
Goldman Sachs
New York
$92K -$33.1K -9,516 -23%
Wells Fargo
29
Wells Fargo
California
$90K +$9.41K +2,708 +9%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$88K +$12.1K +3,468 +13%
HS
31
HighVista Strategies
Massachusetts
$86K +$41.7K +12,000 +66%
OAM
32
Oxford Asset Management
United Kingdom
$80K +$97K +27,906 New
RJA
33
Raymond James & Associates
Florida
$79K +$2.26K +650 +2%
Manulife (Manufacturers Life Insurance)
34
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$79K +$5.19K +1,493 +6%
LPL Financial
35
LPL Financial
California
$76K – – –
AIG
36
American International Group
New York
$72K -$737 -212 -0.8%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$69K – – –
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$67K – – –
VOYA Investment Management
39
VOYA Investment Management
Georgia
$66K +$27.1K +7,797 +51%
MML Investors Services
40
MML Investors Services
Massachusetts
$63K – – –
WS
41
Wedbush Securities
California
$61K – – –
Deutsche Bank
42
Deutsche Bank
Germany
$60K +$32.7K +9,406 +79%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$55K +$21.4K +6,165 +48%
IWM
44
IHT Wealth Management
Illinois
$52K – – –
IGGA
45
Iron Gate Global Advisors
Utah
$49K +$59.4K +17,090 New
CAN
46
Cetera Advisor Networks
California
$47K – – –
CF
47
Centaurus Financial
California
$44K – – –
Squarepoint
48
Squarepoint
New York
$42K +$2.21K +636 +5%
WANY
49
Wealthspire Advisors (New York)
New York
$40K – – –
JP Morgan Chase
50
JP Morgan Chase
New York
$38K – – –
1
2
3 4

GALT Hedge Fund Activity: Q4 2019 in Review

78 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2019, worth a combined $28.8M — down 16% from $34.4M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GALT and 8 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 25 added.

The largest buyer was BlackRock, adding an estimated $995K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $149K.

  • 78 institutional investors held Galectin Therapeutics (GALT) as of Q4 2019, down from 80 in Q3 2019.
  • Funds reported $28.8M of Galectin Therapeutics stock for Q4 2019, down 16% quarter-over-quarter.
  • 8 funds opened new Galectin Therapeutics positions in Q4 2019 and 10 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q4 2019 was BlackRock, an estimated $995K added.
  • The largest Galectin Therapeutics seller in Q4 2019 was Cambridge Investment Research Advisors, an estimated $149K sold.

Based on aggregated 13F filings for Q4 2019.